Equities

Ironwood Pharmaceuticals Inc

Ironwood Pharmaceuticals Inc

Actions
  • Price (EUR)4.10
  • Today's Change0.02 / 0.49%
  • Shares traded0.00
  • 1 Year change-53.93%
  • Beta--
Data delayed at least 15 minutes, as of Nov 13 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments92656620
Total Receivables, Net129115114
Total Inventory------
Prepaid expenses127.728.69
Other current assets, total01.252.37
Total current assets233781745
Property, plant & equipment, net182023
Goodwill, net------
Intangibles, net3.68----
Long term investments------
Note receivable - long term01524
Other long term assets3.610.851.00
Total assets4711,1011,127
LIABILITIES
Accounts payable7.830.480.94
Accrued expenses672543
Notes payable/short-term debt000
Current portion long-term debt/capital leases2000117
Other current liabilities, total1.240.021.32
Total current liabilities27626162
Total long term debt498396337
Total debt698396454
Deferred income tax------
Minority interest------
Other liabilities, total432622
Total liabilities817448521
SHAREHOLDERS EQUITY
Common stock0.160.150.16
Additional paid-in capital1,3551,3491,543
Retained earnings (accumulated deficit)(1699)(696)(938)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(3.03)----
Total equity(346)652606
Total liabilities & shareholders' equity4711,1011,127
Total common shares outstanding156154162
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.